A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas

Trial Profile

A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs Tasquinimod (Primary)
  • Indications Fallopian tube cancer; Gastric cancer; Liver cancer; Ovarian cancer; Peritoneal cancer; Renal cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Umbrella
  • Sponsors Ipsen
  • Most Recent Events

    • 13 Sep 2016 This trial was completed in Belgium, according to European Clinical Trials Database record.
    • 31 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 11 Feb 2015 According to an Active Biotech media release, results from this study are expected in 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top